Status:
COMPLETED
BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
Lead Sponsor:
Bayer
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).
Eligibility Criteria
Inclusion
- 20 years or older
- Japanese male or female
- Non- valvular atrial fibrillation documented by ECG
- Patients aged 60 years and older or with a risk of stroke
Exclusion
- Prior stroke and TIA
- Patients in whom anticoagulants are contraindicated
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00779064
Start Date
July 1 2004
End Date
June 1 2005
Last Update
December 25 2014
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Fukuoka, Fukuoka, Japan, 811-0213
2
Fukuoka, Fukuoka, Japan, 814-0180
3
Kitakyushu, Fukuoka, Japan, 800-0057
4
Koga, Fukuoka, Japan, 807-0051